Chiara Montironi's questions to Y-mAbs Therapeutics Inc (YMAB) leadership • Q1 2025
Question
Chiara Montironi asked about the expected impact of DANYELZA's inclusion in NCCN guidelines and the new COG-led trial on growth and clinician choice, and requested the trial's start timing.
Answer
DANYELZA Business Unit Head Doug Gentilcore explained the NCCN inclusion removes a headwind and puts DANYELZA on equal footing with competitors, creating a tailwind for clinical discussions. He reiterated the trial is expected to start in Q2, likely within 'days than weeks.' CEO Michael Rossi added that they expect the majority of trial enrollment to be completed during the remainder of 2025.